Papers_edited.png

PUBLICATIONS

 
 

ORIGINAL RESEARCH ARTICLES

Click the title of the article to access the PDF

 

INTERNATIONAL JOURNAL OF CANCER
(2020)

NATURE GENETICS
(2020)

Enache O.M.*, Rendo V.*, Abdusamad M., Lam D., Davison D., Pal S., Currimjee N., Hess J., Sanson K., Pantel S., Nag A., Thorner A., Root D., Doench J.G., Vazquez F., Beroukhim R., Golub T.R., and Ben-David U. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nature Genetics (2020). doi: 10.1038/s41588-020-0623-4.

NATURE CANCER
(2020)

Corsello S.M., Nagari R.T., Spangler R.D., Rossen J., Kocak M., Bryan J.G., Humeidi R., Peck D., Wu X., Tang A.A., Wang V.M., Bender S.A., Lemire E., Narayan R., Montgomery P., Ben-David U., Chen Y., Rees M.G., Lyons N.J., McFarland J.M., Wong B.T., Wang L., Dumont N., O'Hearn P.J., Stefan E., Doench J.G., Greulich H., Meyerson M., Vazquez F., Subramanian A., Roth J.A., Bittker J.A., Boehm J.S., Mader C.C., Tsherniak A., and Golub T.R. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nature Cancer (2020). doi: 10.1038/s43018-019-0018-6.

NATURE
(2018)

Ben-David U., Siranosian B., Ha G., Tang H., Oren Y., Hinohara K., Strathdeec.A., Dempster J., Lyons N.J., Burns R., Nag A., Kugener G., Cimini B., Tsvetkov P., Maruvka Y.E., O’Rourke R., Garrity A., Tubelli A.A., Bandopadhayay P., Tsherniak A., Vazquez F., Wong B., Birger C., Ghandi M, Thorner A.R., Bittker J.A., Meyerson M., Getz G., Beroukhim R. and Golub T.R. Genetic and transcriptional evolution alters cancer cell line drug response. Nature, 2018. 560(7718):325-330. doi: 10.1038/s41586-018-0409-3. 

CELL DEATH & DISEASE
(2018)

Abdeen S.A., Ben-David U., Maly B. and Aqueilan R. Somatic loss of WWOX drives triple-negative breast cancer through perturbation of TP53. Cell Death Dis, 2018, 9(8):832. doi: 10.1038/s41419-018-0896-z.

NATURE GENETICS
(2017)

Ben-David U., Ha G., Tseng Y.Y., Greenwald N.F., Oh C., Shih J., McFarland J.M., Wong B., Boehm J.S., Beroukhim R. and Golub T.R. Patient-derived xenografts undergo mouse-specific tumor evolution. Nature Genetics, 2017, 49(11):1567-1575. doi:10.1038/ng.3967.

CLINICAL CANCER RESEARCH
(2016)

Bi W.L., Horowtiz P., Greenwald N., Abedalthagafi M., Agarwalla P.K., Gibson W.J., Mei Y, Schumacher S.E., Ben-David U., Chevalier A., Carter S.L., Tiao G., Brastianos P.K., Ligon A.H., Ducar M., MacConaill L.E., Laws E.R., Santagata S., Beroukhim R., Dunn IF. Landscape of genomic alterations in pituitary adenomas. Clinical Cancer Research, 2016, 23(7):1841-1851. doi: 10.1158/1078-0432.CCR-16-0790. 

CANCER DISCOVERY
(2016)

Aguirre A., Meyers R., Weir B., Vazquez F., Zhang C.Z., Ben-David U., Cook A., Ha G., Harrington W., Doshi M., Gill S., Xu H., Ali L., Jiang G., Pantel S., Lee Y., Goodale A., Cherniack A., Oh C., Kryukov G., Cowley G., Garraway L., Stegmaier K., Roberts C., Golub T.R., Meyerson M., Root D., Tsherniak A., and Hahn W. Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. Cancer Discovery, 2016, 6(8):914-29. doi: 10.1158/2159-8290.CD-16-0154. 

NATURE COMMUNICATIONS
(2016)

Ben-David U., Ha G., Khadka P., Jin X., Wong B., Franke L. and Golub T.R. The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis. Nature Communications, 2016, 7:12160. doi:10.1038/ncomms12160. 

CELL STEM CELL
(2016)

Lamm N., Ben-David U., Kerem B. and Benvenisty N. Genomic instability in human pluripotent stem cells arises from replicative stress and chromosome condensation defects. Cell Stem Cell, 2016, 18(2): 253-61. 

STEM CELLS
(2015)

Ben-David U., Cowell Ian G., Austin Caroline C. and Benvenisty N. Controlling the survival of human pluripotent stem cells by small molecule-based targeting of topoisomerase II alpha. Stem Cells, 2015, 33(3): 1013-9. doi: 10.1002/stem.1888. 

CELL STEM CELL
(2014)

Weissbein U., Ben-David U. and Benvenisty N. Virtual karyotyping revelas greater chromosomal stability in neural cells derived by transdifferentiation than those from stem cells. Cell Stem Cell, 2014, 15(6):687-91. doi: 10.1016/j.stem.2014.10.018.

NATURE COMMUNICATIONS
(2014)

Ben-David U., Arad G., Weissbein U., Mandefro B., Maimon A., Narwani K., Clark A.T., Andrews P.W., Benvenisty N., and Biancotti J.C. Aneuploidy induces profound changes in gene expression, proliferation and tumorigenicity of human pluripotent stem cells. Nature Communications, 2014, 5:4825, doi: 10.1038/ncomms5825.

JOURNAL OF MOLECULAR CELL BIOLOGY
(2014)

Ben-David U.*, Biran A. *, Scaffidi P., Boehringer M., Meshorer E. and Benvenisty N. Elimination of undifferentiated cancer cells by pluripotent stem cell inhibitors. Journal of Molecular Cell Biology, 2014, 6(3):267-9. doi: 10.1093/jmcb/mju012. 

(* Equally contributing first authors)

NATURE PROTOCOLS
(2014)

Ben-David U. and Benvenisty N. Chemical ablation of tumor-initiating human pluripotent stem cells. Nature Protocols, 2014, 9(3):729-40. doi: 10.1038/nprot.2014.050.

NATURE COMMUNICATIONS
(2013)

Ben-David U., Nudel N. and Benvenisty N. Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. Nature Communications, 2013, 4:1992. doi:10.1038/ncomms2992.

CELL STEM CELL
(2013)

Ben-David U., Gan Q.F., Golan-Lev T., Arora P., Yanuka O., Oren Y.S., Leikin-Frenkel A., Graf M., Garippa R., Boehringer M., Gromo G. and Benvenisty N. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell, 2013, 12(2):167-79. doi: 10.1016/j.stem.2012.11.015. 

NATURE COMMUNICATIONS
(2013)

Lee P., Martin N.T., Nakamura K., Azghadi S., Amiri M., Ben-David U., Perlman S., Gatti R.A., Hu H. and Lowry W.E. SMRT compounds abrogate cellular phenotypes of Ataxia Telangiectasia in neural derivatives of patient specific hiPSCs. Nature Communications, 2013, 4:1824. doi:10.1038/ncomms2824.

NATURE PROTOCOLS
(2013)

Ben-David U., Mayshar Y. and Benvenisty N. Virtual karyotyping of pluripotent stem cellson the basis of their global gene expression profiles. Nature Protocols, 2013, 8(5): 989-97.  doi: 10.1038/nprot.2013.051.

STEM CELLS
(2012)

Ben-David U. and Benvenisty N. High prevalence of evolutionarily conserved and species-specific genomic aberrations in mouse pluripotent stem cells. Stem Cells, 2012, 30(4):612-22.doi: 10.1002/stem.1057.

CELL STEM CELL
(2011)

Ben-David U., Mayshar Y. and Benvenisty N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell, 2011, 9(2):97-102.doi: 10.1016/j.stem.2011.06.013.

CELL STEM CELL
(2010)

Mayshar Y.*, Ben-David U.*, Lavon N., Biancotti J.C., Yakir B., Clark A.T., Plath K., Lowry W.E. and Benvenisty N. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell, 2010, 7(4):521-31. doi: 10.1016/j.stem.2010.07.017. (* Equally contributing first authors)

 

REVIEWS, PERSPECTIVES & COMMENTARIES

Click the title of the article to access the PDF

 

MOLECULAR & CELLULAR ONCOLOGY
(2020)

Rendo V., Enache O. and Ben-David U. Adding to the CASeload: Unwarranted p53 signaling induced by Cas9. Mol Cell Oncol, 2020 (in press).

NATURE REVIEWS GENETICS
(2020)

Ben-David U. and Amon A. Context is everything: Aneuploidy in cancer. Nature Reviews Cancer, 2020. doi: 10.1038/s41576-019-0171-x.

NATURE REVIEWS CANCER
(2019)

Ben-David U., Beroukhim R. and Golub T.R. Genomic evolution of cancer models: perils and opportunities. Nature Reviews Cancer, 2019. 19(2):97-109.doi: 10.1038/s41568-018-0095-3.

TRANSPLANTATION
(2018)

Odorico. J., Adams A., Melton D., Greenstein G., Hwa A., Nostro C., Rezania A., Oberholzer J., Pipeleers D., Yang L., Cowan C., Huangfu D., Egli D., Ben-David U., Vallier L., Grey S., Tang Q., Roep B., Ricordi C., Naji A., Orlando G., Anderson D., Poznansky M., Ludwig B., Tomei A., Greiner D., Graham M., Carpenter M., Migliaccio G., D’Amour K., Hering B., Piemonti L., Berney T., Rickels M., Kay T. and Markmann J. Report of the Key Opinion Leaders Meeting on Stem Cell-Derived Beta Cells. Transplantation, 2018, 102(8):1223-1229. doi: 10.1097/TP.0000000000002217. 

STEM CELL REPORTS
(2017)

Andrews P.W., Ben-David U., Benvenisty N., Coffey P., Eggan K., Knowles B.B., Nagy A., Pera M., Reubinoff B., Rugg-Gunn P.J., Stacey G.N. Assessing the safety of human pluripotent stem cells (PSCs) and their derivatives for clinical applications. Stem Cell Reports, 2017, 9(1):1-4. doi: 10.1016/j.stemcr.2017.05.029. 

STEM CELLS TRANSLATIONAL MEDICINE
(2015)

Heslop A.J., Hammond T.G., Santeramo I., Piella A.T., Hopp I., Zhou J., Baty R., Graziano, E.I., Bernabe P., Shaw D.A., Bunn I., Caron A., Skold P., Andrews P.W., Baxter M., Hay D., Hamdam J., Sethu S., Sharpe M.E., Patel S., Jones D.R., Reinhardt J., Danen E.H.J., Ben-David U., Stacey G., Bjorquist P., Rowe, C., Pellegrini G., Antoine D., Cross M.J., Murray P., Williams D., Kitteringham N.R., Park B.K. and Goldring C.E.P. Understanding the risks of stem cell-based therapeutics. Stem Cells Translational Medicine, 2015, 4(4):389-400. doi: 10.5966/sctm.2014-0110. 

BIOCHIMICA ET BIOPHYSICA ACTA
(2015)

Ben-David U. Genomic instability, driver genes and cell selection: Projections from cancer to stem cells. Biochim Biophys Acta, 2014,1849(4):427-35. doi: 10.1016/j.bbagrm.2014.08.005.

JOURNAL OF CELL BIOLOGY
(2014)

Weissbein U., Benvenisty N. and Ben-David U. Genome maintenance in pluripotent stem cells. Journal of Cell Biology 2014, 204(2):153-63.doi: 10.1083/jcb.201310135.

MOLECULAR AND CELLULAR THERAPIES
(2013)

Ben-David U. Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies? Molecular and Cellular Therapies, 2013, 1:3, doi:10.1186/2052-8426-1-3.

CELL
(2013)

Ben-David U., Nissenbaum J. and Benvenisty N. New balance in pluripotency: reprogrammingwith lineage specifiers. Cell, 2013, 153(5): 939-40. doi: 10.1016/j.cell.2013.04.051.

CELL STEM CELL
(2012)

Ben-David U., Kopper O. and Benvenisty N. Expanding the boundaries of embryonic stem cells. Cell Stem Cell, 2012, 10(6):666-77.doi: 10.1016/j.stem.2012.05.003.

CELL STEM CELL
(2012)

Ben-David U., Mayshar Y. and Benvenisty N. Significant acquisition of chromosomal aberrations in human adult mesenchymal stem cells: Response to Sensenbé et al. Cell Stem Cell, 2012, 10(1):10-11. doi: 10.1016/j.stem.2011.12.007.

STEMBOOK
(2012)

Ben-David U. and Benvenisty N. Analyzing the genomic integrity of stem cells. StemBook, 2012. doi: 10.3824/stembook.1.50.1, http://www.stembook.org.

CELL STEM CELL
(2011)

Goldring C.E.P., Duffy P.A., Benvenisty N., Andrews P.W., Ben-David U., Eakins R., French N., Hanley N.A., Kelly L., Kitteringham N.R., Kurth J., Ladenheim D., Laverty H., McBlane J., Narayanan G., Patel S., Reinhardt J, Rossi A., Sharpe M. and Park K. Assessing the safety of stem cell therapeutics. Cell Stem Cell, 2011, 8(6):618-28. doi: 10.1016/j.stem.2011.05.012.

NATURE REVIEWS CANCER
(2011)

Ben-David U. and Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nature Reviews Cancer, 2011, 11(4): 268-77.doi: 10.1038/nrc3034.

CELL CYCLE
(2010)

Ben-David U., Benvenisty N. and Mayshar Y. Genetic instability in human induced pluripotent stem cells: Classification of causes and possible safeguards. 10.4161/cc.9.23.14094. Cell Cycle, 2010, 9(23): 4603-4.

 

©2019 by Ben-David Lab.